Skip to main content

Advertisement

SpringerLink
Log in

Impact of Prior Cancer History on Outcomes of Resected Lung Cancer

  • Thoracic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Previous studies concerning the impact of prior cancer on newly diagnosed lung cancer are mainly based on databases and obtained mixed results. Utilizing a large study population, we aimed to reveal this impact.

Patients and Methods

Lung cancer patients from January 2008 to April 2021 were enrolled. The Kaplan–Meier method was used to perform survival analyses. To investigate the impact of prior cancer, a Cox proportional hazards model was conducted. To minimize the influence of the heterogeneity of prior cancer, stratified analyses were carried out.

Results

In total, 17,423 lung cancer patients were reviewed, among which we identified 1469 (8.4%) patients with a history of prior cancer. Cox regression analysis revealed that prior cancer was an independent poor prognostic factor on overall survival (HR = 1.430, 95% CI: 1.147–1.784, p = 0.001) but did not affect lung cancer-specific survival (HR = 1.120, 95% CI: 0.876–1.434, p = 0.366). Interestingly, in further stratified analyses, we found that prior cancer history affected overall survival only in pTNM stage 0/I patients (HR = 1.670, 95% CI: 1.247–2.237, p = 0.001), but not in pTNM stage II/III/IV patients (HR = 1.237, 95% CI: 0.877–1.743, p = 0.226). Similarly, prior cancer was an independent poor prognostic factor on overall survival only for pN0 patients. Subsequently, subgroup analyses indicated that the impact of prior cancer varied in pTNM stage 0/I patients according to the type of prior cancer and the interval time.

Conclusions

Considering that prior cancer affects overall survival in patients with clinically curable lung cancer, clinicians should pay attention to this effect and improve the management of these patients to achieve a better prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.

    Article  Google Scholar 

  2. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69:363–85.

    Article  Google Scholar 

  3. de Moor JS, Mariotto AB, Parry C, et al. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev. 2013;22:561–70.

    Article  Google Scholar 

  4. Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB. Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol. 2012;30:3734–45.

    Article  Google Scholar 

  5. Keegan THM, Bleyer A, Rosenberg AS, Li Q, Goldfarb M. Second primary malignant neoplasms and survival in adolescent and young adult cancer survivors. JAMA Oncol. 2017;3:1554–7.

    Article  Google Scholar 

  6. Murphy CC, Gerber DE, Pruitt SL. Prevalence of prior cancer among persons newly diagnosed with cancer: an initial report from the surveillance, epidemiology, and end results program. JAMA Oncol. 2018;4:832–6.

    Article  Google Scholar 

  7. Sato A, Matsubayashi K, Morishima T, Nakata K, Kawakami K, Miyashiro I. Increasing trends in the prevalence of prior cancer in newly diagnosed lung, stomach, colorectal, breast, cervical, and corpus uterine cancer patients: a population-based study. BMC Cancer. 2021;21:264.

    Article  Google Scholar 

  8. Gerber DE, Laccetti AL, Xuan L, Halm EA, Pruitt SL. Impact of prior cancer on eligibility for lung cancer clinical trials. J Natl Cancer Inst. 2014. https://doi.org/10.1093/jnci/dju302.

    Article  Google Scholar 

  9. Monsalve AF, Hoag JR, Resio BJ, et al. Variable impact of prior cancer history on the survival of lung cancer patients. Lung Cancer. 2019;127:130–7.

    Article  Google Scholar 

  10. Laccetti AL, Pruitt SL, Xuan L, Halm EA, Gerber DE. Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual. J Natl Cancer Inst. 2015. https://doi.org/10.1093/jnci/djv002.

    Article  Google Scholar 

  11. Laccetti AL, Pruitt SL, Xuan L, Halm EA, Gerber DE. Prior cancer does not adversely affect survival in locally advanced lung cancer: a national SEER-medicare analysis. Lung Cancer. 2016;98:106–13.

    Article  Google Scholar 

  12. Pruitt SL, Laccetti AL, Xuan L, Halm EA, Gerber DE. Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer. Br J Cancer. 2017;116:717–25.

    Article  Google Scholar 

  13. Liu J, Zhou H, Zhang Y, et al. Impact of prior cancer history on the overall survival of younger patients with lung cancer. ESMO Open. 2020. https://doi.org/10.1136/esmoopen-2019-000608.

    Article  Google Scholar 

  14. López-Encuentra A, de la Gómez Cámara A, Rami-Porta R, Duque-Medina JL, de Nicolás JL, Sayas J. Previous tumour as a prognostic factor in stage I non-small cell lung cancer. Thorax. 2007;62:386–90.

    Article  Google Scholar 

  15. Aguiló R, Macià F, Porta M, Casamitjana M, Minguella J, Novoa AM. Multiple independent primary cancers do not adversely affect survival of the lung cancer patient. Eur J Cardiothorac Surg. 2008;34:1075–80.

    Article  Google Scholar 

  16. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51.

    Article  Google Scholar 

  17. Zhang Y, Ma X, Shen X, et al. Surgery for pre- and minimally invasive lung adenocarcinoma. J Thorac Cardiovasc Surg. 2022;163(2):456–64.

    Article  Google Scholar 

Download references

Acknowledgment

This work was supported by the National Natural Science Foundation of China (81930073), the Shanghai Science and Technology Innovation Action Project (20JC1417200), and the Cooperation Project of Conquering Major Diseases in Xuhui District (XHLHGG202101).

Author information

Author notes

  1. Di Li and Chaoqiang Deng contributed equally to this paper.

  2. Yang Zhang and Haiquan Chen contributed equally as co-senior and corresponding authors.

Authors and Affiliations

  1. Department of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China

    Di Li MD, Chaoqiang Deng MD, Fangqiu Fu MD, Jinsong Bai MD, Yang Zhang MD & Haiquan Chen MD, PhD

  2. Institute of Thoracic Oncology, Fudan University, Shanghai, China

    Di Li MD, Chaoqiang Deng MD, Fangqiu Fu MD, Jinsong Bai MD, Yuan Li MD, PhD, Yang Zhang MD & Haiquan Chen MD, PhD

  3. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

    Di Li MD, Chaoqiang Deng MD, Fangqiu Fu MD, Jinsong Bai MD, Yuan Li MD, PhD, Yang Zhang MD & Haiquan Chen MD, PhD

  4. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China

    Yuan Li MD, PhD

Authors
  1. Di Li MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chaoqiang Deng MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fangqiu Fu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jinsong Bai MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuan Li MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yang Zhang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Haiquan Chen MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yang Zhang MD or Haiquan Chen MD, PhD.

Ethics declarations

Disclosure

The authors declare no potential conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (JPG 314 kb)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, D., Deng, C., Fu, F. et al. Impact of Prior Cancer History on Outcomes of Resected Lung Cancer. Ann Surg Oncol 30, 1534–1540 (2023). https://doi.org/10.1245/s10434-022-12597-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-022-12597-8

Search

Navigation